Acute myeloblastic leukemia in a patient with hereditary protein C deficiency.
The patient had been diagnosed with hereditary protein C deficiency. She recently developed acute myeloblastic leukemia (AML). Chemotherapy for AML by cytosine arabinoside, aclarubicin followed by granulocyte colony-stimulating factor (CAG) was started. Disseminated intravascular coagulation (DIC) was observed, however thromboembolic complication was not observed during the hospital course. Hematological remission was not obtained, and the patient died of pseudomembranous pancolitis. Whether the development of these rare disorders of hereditary protein C and AML are coincidental, or involve a causal relationship remains unknown.
Matsui
Kumiko
K
Division of Hematology, Department of Medicine, Yamaguchi Prefectural Medical Center, Osaki, Hofu.
Tanaka
Yoshinori
Y
Yamashita
Koji
K
Matsuda
Kazuhiro
K
Shinohara
Kenji
K
D015250:Aclarubicin / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004761:Enterocolitis, Pseudomembranous / Q000209:etiology / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008875:Middle Aged; D020151:Protein C Deficiency / Q000150:complications / Q000188:drug therapy / Q000473:pathology
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin